DE69229640D1 - Teilchen, methode zur herstellung der teilchen und deren verwendung - Google Patents

Teilchen, methode zur herstellung der teilchen und deren verwendung

Info

Publication number
DE69229640D1
DE69229640D1 DE69229640T DE69229640T DE69229640D1 DE 69229640 D1 DE69229640 D1 DE 69229640D1 DE 69229640 T DE69229640 T DE 69229640T DE 69229640 T DE69229640 T DE 69229640T DE 69229640 D1 DE69229640 D1 DE 69229640D1
Authority
DE
Germany
Prior art keywords
phase
particles
pct
homogeneous
date apr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69229640T
Other languages
English (en)
Other versions
DE69229640T2 (de
Inventor
Tomas Landh
Kare Larssons
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandberg Development AB
Original Assignee
GS Development AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GS Development AB filed Critical GS Development AB
Priority claimed from PCT/SE1992/000692 external-priority patent/WO1993006921A1/en
Application granted granted Critical
Publication of DE69229640D1 publication Critical patent/DE69229640D1/de
Publication of DE69229640T2 publication Critical patent/DE69229640T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K19/00—Liquid crystal materials
    • C09K19/02—Liquid crystal materials characterised by optical, electrical or physical properties of the components, in general
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K19/00—Liquid crystal materials
    • C09K19/52—Liquid crystal materials characterised by components which are not liquid crystals, e.g. additives with special physical aspect: solvents, solid particles
    • C09K19/54—Additives having no specific mesophase characterised by their chemical composition
    • C09K19/542—Macromolecular compounds
    • C09K19/544—Macromolecular compounds as dispersing or encapsulating medium around the liquid crystal
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K19/00—Liquid crystal materials
    • C09K19/52—Liquid crystal materials characterised by components which are not liquid crystals, e.g. additives with special physical aspect: solvents, solid particles
    • C09K2019/528—Surfactants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S516/00—Colloid systems and wetting agents; subcombinations thereof; processes of
    • Y10S516/90—Liquid crystal material of, or for, colloid system, e.g. g phase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Saccharide Compounds (AREA)
DE69229640T 1991-10-04 1992-10-02 Teilchen, methode zur herstellung der teilchen und deren verwendung Expired - Lifetime DE69229640T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77101491A 1991-10-04 1991-10-04
PCT/SE1992/000692 WO1993006921A1 (en) 1991-10-04 1992-10-02 Particles, method of preparing said particles and uses thereof

Publications (2)

Publication Number Publication Date
DE69229640D1 true DE69229640D1 (de) 1999-08-26
DE69229640T2 DE69229640T2 (de) 1999-12-16

Family

ID=25090424

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69229640T Expired - Lifetime DE69229640T2 (de) 1991-10-04 1992-10-02 Teilchen, methode zur herstellung der teilchen und deren verwendung

Country Status (10)

Country Link
US (1) US5531925A (de)
EP (1) EP0643620B1 (de)
JP (1) JP3571717B2 (de)
AT (1) ATE182278T1 (de)
AU (1) AU2699892A (de)
BR (1) BR9206593A (de)
CA (1) CA2120359C (de)
DE (1) DE69229640T2 (de)
ES (1) ES2133391T3 (de)
FI (1) FI941538A (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA929870B (en) * 1991-12-23 1993-08-18 Duphar Int Res Adjuvants
US6277410B1 (en) 1992-10-08 2001-08-21 Supratek Pharma Inc. Copolymer compositions for oral delivery
US6153193A (en) * 1993-04-28 2000-11-28 Supratek Pharma Inc. Compositions for targeting biological agents
FR2726762B1 (fr) * 1994-11-10 1997-01-17 Oreal Composition cosmetique ou dermatologique sous forme d'une dispersion d'une phase huileuse dans une phase aqueuse stabilisee a l'aide de particules de gel cubique et son procede d'obtention
US6221959B1 (en) 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
US6359054B1 (en) 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration
US6353055B1 (en) 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
US6040295A (en) 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
JPH08254688A (ja) * 1995-03-16 1996-10-01 Toshiba Corp 液晶表示素子
JPH11510142A (ja) 1995-07-21 1999-09-07 ブラウン・ユニバーシティ・リサーチ・ファンデーション 核酸負荷ポリマー微粒子を使用した遺伝子治療法
US6248720B1 (en) * 1996-07-03 2001-06-19 Brown University Research Foundation Method for gene therapy using nucleic acid loaded polymeric microparticles
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
JP2000500744A (ja) * 1995-11-09 2000-01-25 マイクロバイオロジカル リサーチ オーソリティー ワクチン接種および遺伝子治療のためのマイクロカプセル化ｄｎａ
US6284375B1 (en) * 1996-10-18 2001-09-04 Tuo Jin Lipid vesicle system
US20020182258A1 (en) * 1997-01-22 2002-12-05 Zycos Inc., A Delaware Corporation Microparticles for delivery of nucleic acid
US5783567A (en) * 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
US6106609A (en) * 1997-04-08 2000-08-22 The United States Of America As Represented By The Secretary Of The Navy Formation of nanocrystalline semiconductor particles within a bicontinuous cubic phase
DE69710442T2 (de) * 1997-05-02 2002-10-02 Takasago International Corp., Tokio/Tokyo Flüssigkristallphase enthaltende Lipidzusammensetzung
US5962015A (en) * 1997-05-02 1999-10-05 Kobo Products S.A.R.L. Stabilized liposomes
US6638621B2 (en) * 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
JP4792149B2 (ja) * 1997-09-09 2011-10-12 リオトロピック セラピュティックス アイエヌシー． 被覆粒子とその製造法及び使用法
SE9703458D0 (sv) * 1997-09-25 1997-09-25 Pharmacia & Upjohn Ab Nicotine compositions and methods of formulation thereof
US6406719B1 (en) 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
WO1999065531A1 (en) 1998-06-18 1999-12-23 Johns Hopkins University School Of Medicine Polymers for delivery of nucleic acids
US6916490B1 (en) 1998-07-23 2005-07-12 UAB Research Center Controlled release of bioactive substances
US6558961B1 (en) * 1998-09-04 2003-05-06 Powderject Research Limited Immunodiagnostics using particle delivery methods
WO2001010411A2 (de) * 1999-08-06 2001-02-15 Max-Delbrück-Centrum für Molekulare Medizin Implantierbares wirkstoffdepot
US20050037086A1 (en) * 1999-11-19 2005-02-17 Zycos Inc., A Delaware Corporation Continuous-flow method for preparing microparticles
KR20010100194A (ko) * 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
JP2003535122A (ja) * 2000-06-02 2003-11-25 ザイコス インク． 生物活性物質のための送達システム
US20020153508A1 (en) * 2000-06-29 2002-10-24 Lynch Matthew Lawrence Cubic liquid crystalline compositions and methods for their preparation
US20040266983A1 (en) * 2000-08-17 2004-12-30 Reeve Lorraine E Purified polyoxyalkylene block copolymers
DE10057770A1 (de) * 2000-11-22 2002-05-23 Beiersdorf Ag Hautpflegeprodukte mit einem Gehalt an dispersen Flüssigkristallen, welche kubische Phasen darstellen ,
CA2428993C (en) * 2000-11-29 2011-05-31 Lyotropic Therapeutics, Inc. Solvent systems for pharmaceutical agents
US7008646B2 (en) 2001-02-20 2006-03-07 Patrick Thomas Spicer Cubic liquid crystalline compositions and methods for their preparation
US6936187B2 (en) * 2001-02-21 2005-08-30 Matthew Lawrence Lynch Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
US6656385B2 (en) * 2001-02-21 2003-12-02 The Procter & Gamble Company Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
US20030060695A1 (en) * 2001-03-07 2003-03-27 Connelly Patrick R. Implantable artificial organ devices
EP1408932A4 (de) * 2001-06-23 2009-02-25 Lyotropic Therapeutics Inc Teilchen mit verbesserter solubilisierungseigenschaft
GB0118300D0 (en) * 2001-07-26 2001-09-19 Cortendo Ab Formulations
WO2003013683A1 (en) * 2001-08-08 2003-02-20 Brown University Research Foundation Methods for micronization of hydrophobic drugs
US20040022820A1 (en) * 2001-11-28 2004-02-05 David Anderson Reversed liquid crystalline phases with non-paraffin hydrophobes
WO2003049701A2 (en) * 2001-12-10 2003-06-19 Spherics, Inc. Methods and products useful in the formation and isolation of microparticles
WO2003090693A2 (en) * 2002-04-23 2003-11-06 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing lamotrigine particles of defined morphology
US20040018237A1 (en) * 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
US20030232340A1 (en) * 2002-06-13 2003-12-18 David Anderson Nanoporous particle with a retained target
EP1534512A4 (de) * 2002-06-13 2009-04-29 Lyotropic Therapeutics Inc Beschichtete teilchen, herstellungs- und verwendungsverfahren
US20040156816A1 (en) * 2002-08-06 2004-08-12 David Anderson Lipid-drug complexes in reversed liquid and liquid crystalline phases
GB0305941D0 (en) * 2003-03-14 2003-04-23 Camurus Ab Composition
US20050119340A1 (en) * 2003-06-13 2005-06-02 David Anderson Treatment methods with low-dose, longer-acting formulations of local anesthetics and other agents
ATE411101T1 (de) * 2003-08-04 2008-10-15 Camurus Ab Verfahren zum beladen von amphiphilen teilchen mit wirkstoffen
EP1667656A4 (de) * 2003-09-01 2011-12-28 Mayne Pharma Int Pty Ltd Zusammensetzungen und verfahren zur abgabe von biologisch wirksamen mitteln
GB0322033D0 (en) * 2003-09-19 2003-10-22 Camurus Ab Composition
NZ545744A (en) 2003-09-22 2009-12-24 Baxter Int High-pressure sterilization to terminally sterilize pharmaceutical preparations and medical products
US20070293441A1 (en) * 2003-09-22 2007-12-20 Baxter International Inc. High-pressure sterilization to terminally sterilize pharmaceutical preparations and medical products
US7713440B2 (en) * 2003-10-08 2010-05-11 Lyotropic Therapeutics, Inc. Stabilized uncoated particles of reversed liquid crystalline phase materials
WO2006075124A1 (en) * 2005-01-14 2006-07-20 Camurus Ab Somatostatin analogue formulations
US8865021B2 (en) * 2003-11-07 2014-10-21 Camurus Ab Compositions of lipids and cationic peptides
EP1713446B1 (de) 2004-01-23 2010-12-01 Camurus Ab Ternäre nichtlamellare lipidzusammensetzungen
GB0401513D0 (en) * 2004-01-23 2004-02-25 Camurus Ab Compositions
EP1598060A1 (de) * 2004-05-18 2005-11-23 Nestec S.A. Öl-in-Wasser-Emulsion für Lieferung
CA2575906C (en) * 2004-08-04 2014-04-15 Camurus Ab Compositions forming non-lamellar dispersions
GB0417388D0 (en) * 2004-08-04 2004-09-08 Camurus Ab Composition
US20060127437A1 (en) * 2004-12-13 2006-06-15 Misty Anderson Kennedy Semisolid system and combination semisolid, multiparticulate system for sealing tissues and/or controlling biological fluids
US20070059350A1 (en) * 2004-12-13 2007-03-15 Kennedy John P Agents for controlling biological fluids and methods of use thereof
US8535709B2 (en) * 2004-12-13 2013-09-17 Southeastern Medical Technologies, Llc Agents for controlling biological fluids and methods of use thereof
SI1845942T1 (sl) * 2005-01-14 2014-06-30 Camurus Ab Gnrh analogne formulacije
DE602005026998D1 (de) * 2005-01-14 2011-04-28 Camurus Ab Somatostatin-analog-formulierungen
US9649382B2 (en) 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
KR101245022B1 (ko) * 2005-01-21 2013-03-19 카무러스 에이비 약제학적 지질 조성물
GB0501364D0 (en) * 2005-01-21 2005-03-02 Camurus Ab Compositions
US7125954B2 (en) 2005-01-27 2006-10-24 General Electric Company Method for producing polyether polymers
CA2609810C (en) * 2005-06-06 2012-05-22 Camurus Ab Glp-1 analogue formulations
WO2008034082A2 (en) * 2006-09-15 2008-03-20 Maroon Biotech, Corporation Method of using amphiphilic multiblock copolymers in food
CZ299218B6 (cs) * 2006-11-07 2008-05-21 Zentiva, A. S. Kompozice depotních olanzapinových injekcních systému
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
JP2008120838A (ja) * 2008-02-21 2008-05-29 Medgel Corp 配位結合を利用した薬物−高分子複合体製剤の調製方法
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
US8603999B2 (en) 2008-12-05 2013-12-10 Commonwealth Scientific And Industrial Research Organisation Amphiphile prodrugs
US9080973B2 (en) * 2009-04-22 2015-07-14 Wisconsin Alumni Research Foundation Analyte detection using liquid crystals
WO2013168167A1 (en) 2012-05-10 2013-11-14 Painreform Ltd. Depot formulations of a hydrophobic active ingredient and methods for preparation thereof
CA2874367C (en) 2012-05-25 2020-08-18 Camurus Ab Somatostatin receptor agonist formulations
RU2710551C2 (ru) * 2014-03-25 2019-12-27 Дженентек, Инк. Способы приготовления полоксамера для применения в клеточной культуральной среде
CA3003397A1 (en) 2014-10-30 2016-05-06 Textile-Based Delivery, Inc. Delivery systems
WO2019241853A1 (en) 2018-06-21 2019-12-26 NanoMed Holdings Pty Ltd Platinum-based amphiphile prodrugs
EP4100029A4 (de) * 2020-02-03 2024-03-06 Curemast, Inc. Zusammensetzungen und verwendungsverfahren dafür zur behandlung von mastitis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8206744D0 (sv) * 1982-11-26 1982-11-26 Fluidcarbon International Ab Preparat for kontrollerad avgivning av substanser
US4556289A (en) * 1983-03-21 1985-12-03 Manchester R & D Partnership Low birefringence encapsulated liquid crystal and optical shutter using same
US5371109A (en) * 1986-07-01 1994-12-06 Drilletten Ab Controlled release composition for a biologically active material dissolved or dispersed in an L2-phase
GB8803037D0 (en) * 1988-02-10 1988-03-09 Unilever Plc Aqueous detergent compositions & methods of forming them
US5030452A (en) * 1989-01-12 1991-07-09 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
US5108756A (en) * 1989-01-12 1992-04-28 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
US5143934A (en) * 1990-11-21 1992-09-01 A/S Dumex (Dumex Ltd.) Method and composition for controlled delivery of biologically active agents
JPH03139525A (ja) * 1989-10-24 1991-06-13 Sunstar Eng Inc 紫外線硬化性組成物

Also Published As

Publication number Publication date
BR9206593A (pt) 1995-11-28
EP0643620B1 (de) 1999-07-21
FI941538A (fi) 1994-05-31
DE69229640T2 (de) 1999-12-16
ATE182278T1 (de) 1999-08-15
FI941538A0 (fi) 1994-03-31
EP0643620A1 (de) 1995-03-22
JP3571717B2 (ja) 2004-09-29
JPH07502197A (ja) 1995-03-09
CA2120359C (en) 2000-12-26
US5531925A (en) 1996-07-02
CA2120359A1 (en) 1993-04-15
AU2699892A (en) 1993-05-03
ES2133391T3 (es) 1999-09-16

Similar Documents

Publication Publication Date Title
DE69229640D1 (de) Teilchen, methode zur herstellung der teilchen und deren verwendung
NO941191L (no) Partikler, fremgangsmåte for fremstilling samt anvendelse av slike
AU3506893A (en) Use of fullerenes in diagnostic and/or therapeutic agents
FI953442A (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
KR950703954A (ko) 외상 손상과 관련된 신경학적 병변의 치료에서 릴루졸의 적용(application of riluzole in the treatment of neurological lesions related to traumatic injuries)
ATE195740T1 (de) Glucosamin-disaccharide, verfahren zu deren herstellung, pharmazeutische präparate davon und ihre verwendung
FR05C0045I2 (de)
IL109448A0 (en) Risperidone pamoate, its preparation and pharmaceutical compositions containing it
BG102708A (en) 4-aminopyrimidine derivatives, medicamentous preparations containing them, their application and method for their preparation
CA2098814A1 (en) Method of producing microscopic particles made of hydrolytically decomposable polymers and containing active substances
ZA952555B (en) Lipopeptide derivatives a process for their preparation and their use
AU6194286A (en) New carboxylic acid derivatives, their manufacturing process,use and medicines containing these compounds
EP0137440A3 (de) Cephalosporinderivate und Verfahren zu ihrer Herstellung
IL106121A0 (en) Dna sequences with oligosaccharide transporter,plasmids,bacteria and plants containing a transporter as well as a process for the preparation and transformation of yeast strains for identification of the transporter
ATE59757T1 (de) Phospholipidhaltige produkte, deren herstellung und verwendung.
HUT68239A (en) Process for producing inclusion complexes of nimesulide alkali salts with cyclodextrins or cyclodextrin derivatives and pharmaceutical preparations containing them
GR3026324T3 (en) Use of prostacyclin derivatives to prevent or treat disorders of the microcirculating system when x-ray, nmr or ultrasonic contrasting agents are administered.
NO307933B1 (no) Vann-uløselig eller lite vannløselig terapeutisk forbindelse, anvendelse derav samt farmasøytisk blanding inneholdende nevnte forbindelse
GB2349335A (en) Compositions
GR3008746T3 (de)
EP0487996B1 (de) 3-substituierte Cephalosporine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
IL107917A0 (en) Triazoloquinazolines, their preparation and their use as medicaments
HUT70477A (en) Leukotriene-b4 derivatives, process for preparing the same and medicaments contg. them cont. the same
ES2161243T3 (es) Imidazolo-quinoxalinonas para el tratamiento de enfermedades del sistema nervioso central.
EP0281092A3 (de) Cephalosporinderivate und Verfahren zu ihrer Herstellung

Legal Events

Date Code Title Description
R071 Expiry of right

Ref document number: 643620

Country of ref document: EP